Recommendations for the use of Lyme disease vaccine
19, 1999--Rubin-Ehrenthal and Associates (RE&A), the consumer division of Healthworld Corporation, (NASDAQ: HWLD) has announced that a major direct-to-consumer advertising campaign for LYMErix(TM) Lyme disease vaccine
from client SmithKline Beecham, began yesterday.
To the Editor: The recent article by Meltzer and colleagues (1) is an :important contribution to a pertinent public health issue: who should receive the newly licensed Lyme disease vaccine
Decorin Binding Protein has always shown promise as a second generation Lyme disease vaccine
candidate in that it actively targets the disease-causing bacterium, B.
Kravitz recommends that people who are at high risk for tick exposure consider getting a Lyme disease vaccine
, this would include people who work outside or spend lots of time outdoors in high-risk counties.
Although experiments have shown that a Lyme disease vaccine
using rOspA is safe and immunogenic in both animals and humans (17-23), no data have been published concerning the decrease in antibody levels over more than 20 months (9).
April 13 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota announced today that it will cover the Lyme Disease vaccine
, LYMErix(TM), using established guidelines adopted by the Minnesota Department of Health.
We are continuing to advance our RSV and Lyme disease vaccine
programs and anticipate that our partner, Pasteur Merieux Connaught, will have begun clinical trials of both of these vaccines by mid 1999.
Pasteur Merieux Connaught's candidate Lyme disease vaccine
complete clinical trials designed to study a Lyme disease vaccine
that as a Lyme disease vaccine
candidate, DBP may provide advantages
MedImmune is developing a Lyme disease vaccine
which is being evaluated in Phase I clinical trials and is collaborating with investigators at Texas A&M on a new vaccine candidate.
Several vaccines under development by MedImmune, including a Lyme disease vaccine
beginning clinical trials, employ recombinant BCG technology.
The vaccine, called LymeVax, was the first Lyme disease vaccine
developed for any species, including humans, when it was introduced in 1990.
Companies developing Lyme disease vaccines
have already expressed an interest in such models, he adds.